Conferences - Results from #8000

ASCO 2018: Alterations in Key Clear Cell Renal Cell Carcinoma Genes to Refine Patient Prognosis June 3, 2018

ASCO 2018: Phase II Trial of Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations June 3, 2018

ASCO 2018: Apache: Open Label, Randomized, Phase 2 Study of Durvalumab, Alone or in Combination with Tremelimumab, in Patients with Advanced Germ Cell Tumors: Results at the End of First Stage June 3, 2018

ASCO 2018: Characterizing Tumor Immune Microenvironment and Outcomes for 409 Patients Treated On COMPARZ: Distinct Clusters Emphasize Immune Infiltration Vs. Angiogenesis June 3, 2018

ASCO 2018: VinCaP: A Phase II Trial of Vinflunine Chemotherapy in Locally-Advanced and Metastatic Carcinoma of the Penis (CRUK/12/021) June 3, 2018

ASCO 2018: Genomics Versus Genetics and Implications for Prostate Cancer Care June 3, 2018

ASCO 2018: Prostate Radiotherapy in Newly-Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: A Single-Institution Experience June 2, 2018

ASCO 2018: The Complete Genomic Landscape of Metastatic Prostate Cancer Pinpoints Clinically Targetable Subgroups June 2, 2018

ASCO 2018: Abi Race: A Prospective, Multicenter Study of Black and White Patients with Metastatic Castrate Resistant Prostate Cancer Treated with Abiraterone Acetate and Prednisone June 2, 2018

ASCO 2018: Oligometastasis from Conception to Treatment June 2, 2018

ASCO 2018: When Your Patient 'Friends' You: Appropriate Communication With Patients and Families Online June 2, 2018

ASCO 2018: Practical Guidance on Genetic Counseling Without Genetic Counselor Support June 2, 2018

ASCO 2018: Gut Microbiome Composition to Predict Resistance in Renal Cell Carcinoma Patients on Nivolumab June 2, 2018

ASCO 2018: Evaluating the Efficacy and Safety of the Oral CXCR4 Inhibitor X4P-001 in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma June 2, 2018

ASCO 2018: Pegilodecakin with Nivolumab or Pembrolizumab in Patients with Metastatic Renal Cell Carcinoma June 2, 2018

ASCO 2018: Pembrolizumab versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer: 2-Year Follow-Up from KEYNOTE-045 Trial June 2, 2018

ASCO 2018: A Subgroup Analysis of the East Asia Population in RANGE June 2, 2018

ASCO 2018: Risks versus Benefits: Using Social Media Safely June 2, 2018

ASCO 2018: How I Do It: Precision Medicine for Prostate Cancer in the Real World June 2, 2018

ASCO 2018: Prognostic Biomarkers in the "Precise" Management of Kidney Cancer June 2, 2018

Page 401 of 616